fMRI B-E
study I-E
of O
neural O
sensitization O
to O
hedonic O
stimuli O
in O
long‐term O
, O
daily B-E
cannabis I-E
users I-E
Abstract O
Although O
there O
is O
emergent O
evidence O
illustrating O
neural O
sensitivity O
to O
cannabis O
cues O
in O
cannabis O
users O
, O
the O
specificity O
of O
this O
effect O
to O
cannabis O
cues O
as O
opposed O
to O
a O
generalized O
hyper‐sensitivity O
to O
hedonic O
stimuli O
has O
not O
yet O
been O
directly O
tested O
. O

Using O
fMRI B-E
, O
we O
presented O
53 O
daily O
, O
long‐term B-E
cannabis I-E
users I-E
and O
68 O
non‐using B-E
controls I-E
visual I-E
and O
tactile O
cues O
for O
cannabis O
, O
a O
natural O
reward O
, O
and O
, O
a O
sensory‐perceptual O
control O
object O
to O
evaluate O
brain O
response O
to O
hedonic O
stimuli O
in O
cannabis O
users O
. O

The O
results O
showed O
an O
interaction O
between O
group O
and O
reward O
type O
such O
that O
the O
users O
had O
greater O
response O
during O
cannabis O
cues O
relative O
to O
natural O
reward O
cues O
( O
i.e O
. O
, O
fruit O
) O
in O
the O
orbitofrontal O
cortex O
, O
striatum O
, O
anterior O
cingulate O
gyrus O
, O
and O
ventral O
tegmental O
area O
compared O
to O
non‐users O
( O
cluster‐threshold O
z O
= O
2.3 O
, O
P O
< O
0.05 O
) O
. O

In O
the O
users O
, O
there O
were O
positive O
brain‐behavior O
correlations O
between O
neural O
response O
to O
cannabis O
cues O
in O
fronto‐striatal‐temporal O
regions O
and O
subjective O
craving O
, O
marijuana‐related O
problems O
, O
withdrawal O
symptoms O
, O
and O
levels O
of O
THC O
metabolites O
( O
cluster‐threshold O
z O
= O
2.3 O
, O
P O
< O
0.05 O
) O
. O

These O
findings O
demonstrate O
hyper‐responsivity O
, O
and O
, O
specificity O
of O
brain O
response O
to O
cannabis O
cues O
in O
long‐term O
cannabis O
users O
that O
are O
above O
that O
of O
response O
to O
natural O
reward O
cues O
. O

These O
observations O
are O
concordant O
with O
incentive O
sensitization O
models O
suggesting O
sensitization O
of O
mesocorticolimbic O
regions O
and O
disruption O
of O
natural O
reward O
processes O
following O
drug O
use O
. O

Although O
the O
cross‐sectional O
nature O
of O
this O
study O
does O
not O
provide O
information O
on O
causality O
, O
the O
positive O
correlations O
between O
neural O
response O
and O
indicators O
of O
cannabis O
use O
( O
i.e O
. O
, O
THC O
levels O
) O
suggest O
that O
alterations O
in O
the O
reward O
system O
are O
, O
in O
part O
, O
related O
to O
cannabis O
use O
. O

Hum O
Brain O
Mapp O
37 O
: O
3431 O
– O
3443 O
, O
2016 O
. O
© O
2016 O
The O
Authors O
Human O
Brain O
Mapping O
Published O
by O
Wiley O
Periodicals O
, O
Inc O
. O

MATERIALS B-E
AND I-E
METHODS I-E
This O
study O
was O
approved O
by O
the O
University O
of O
Texas O
at O
Dallas O
and O
University O
of O
Texas O
Southwestern O
Medical O
Center O
Institutional O
Review O
Boards O
. O

This O
study O
was O
conducted O
according O
to O
the O
principles O
expressed O
in O
the O
Declaration O
of O
Helsinki O
. O

All O
participants O
provided O
informed O
written O
consent O
to O
participate O
in O
the O
study O
and O
were O
provided O
monetary O
compensation O
for O
their O
participation O
. O

Participants O
Fifty O
nine O
regular O
cannabis O
users O
and O
70 O
non‐users O
participated O
in O
this O
study O
. O

The O
study's O
inclusion O
criteria O
were O
: O
right‐handedness O
, O
English O
as O
the O
primary O
language O
, O
absence O
of O
current O
or O
history O
of O
psychosis O
, O
traumatic O
brain O
injury O
, O
and O
MRI O
contraindications O
( O
e.g O
. O
, O
pregnancy O
, O
non‐removal O
metallic O
implants O
, O
claustrophobia O
) O
. O

All O
of O
the O
participants O
were O
screened O
via O
urinalysis O
for O
other O
drugs O
of O
abuse O
and O
were O
excluded O
if O
drugs O
( O
other O
than O
cannabis O
) O
were O
detected O
. O

Participants O
were O
excluded O
for O
regular O
tobacco O
use O
as O
defined O
by O
smoking O
more O
than O
a O
pack O
of O
cigarettes O
a O
month O
as O
well O
as O
current O
alcohol O
dependence O
based O
on O
the O
Structured O
Clinical O
Interview O
for O
DSM‐IV O
( O
SCID O
) O
[ O
First O
et O
al O
. O
, O
1997 O
] O
. O

Cannabis O
users O
were O
recruited O
based O
on O
self‐reported O
history O
of O
regular O
cannabis O
use O
with O
a O
minimum O
of O
5,000 O
lifetime O
occasions O
, O
as O
well O
as O
daily O
use O
over O
the O
preceding O
60 O
days O
. O

Verification O
of O
cannabis O
use O
was O
conducted O
via O
quantification O
of O
THC O
metabolites O
as O
ng O
/ O
ml O
( O
over O
creatinine O
) O
via O
gas O
chromatography O
( O
GC O
) O
/ O
mass O
spectroscopy O
( O
MS O
) O
. O

The O
non‐using O
controls O
were O
recruited O
based O
on O
the O
absence O
of O
daily O
cannabis O
use O
at O
any O
period O
in O
their O
lifetime O
, O
in O
addition O
to O
no O
current O
illicit O
drug O
use O
in O
the O
past O
60 O
days O
. O

Behavioral O
Data O
We O
collected O
( O
1 O
) O
the O
Marijuana B-E
Craving I-E
Questionnaire I-E
( I-E
MCQ I-E
) I-E
[ O
Heishman O
et O
al O
. O
, O
2001 O
] O
to O
measure O
basal O
level O
craving O
for O
cannabis O
immediately O
prior O
to O
and O
after O
the O
MRI O
scan O
and O
, O
( O
2 O
) O
the O
Marijuana O
Withdrawal O
Checklist O
, O
( O
MWC O
) O
[ O
Budney O
et O
al O
. O
, O
1999 O
] O
to O
measure O
self‐reported O
withdrawal O
symptoms O
immediately O
prior O
to O
the O
MRI O
scan O
, O
and O
, O
( O
3 O
) O
the O
Marijuana O
Problems O
Survey O
( O
MPS O
) O
[ O
Stephens O
et O
al O
. O
, O
2000 O
] O
to O
measure O
problems O
associated O
with O
cannabis O
use O
. O

Information O
pertaining O
to O
self‐reported O
grams O
of O
cannabis O
use O
per O
day O
was O
also O
obtained O
from O
the O
cannabis O
users O
. O

Behavioral O
Data O
Analyses O
T‐tests O
and O
chi‐square O
tests O
were O
used O
in O
SPSS O
21 O
for O
descriptive O
purposes O
as O
well O
as O
to O
compare O
the O
groups O
on O
demographic O
and O
substance O
use O
variables O
( O
Table O
1 O
) O
. O

Demographic O
and O
substance O
use O
characteristics O
of O
participants O
Users O
mean O
( O
SD O
) O
Non‐users O
mean O
( O
SD O
) O
Group O
difference O
N O
53 O
68 O
— O
Age O
30.66 O
( O
7.48 O
) O
31.41 O
( O
10.20 O
) O
t O
( O
118.59 O
) O
= O
0.467 O
; O
P O
= O
0.641 O
Males O
( O
N O
, O
% O
) O
33 O
, O
62.3% O
33 O
, O
48.5% O
χ2 O
( O
1 O
) O
= O
2.267 O
; O
P O
= O
0.132 O
Years O
of O
education O
13.06 O
( O
3.05 O
) O
16.83 O
( O
2.79 O
) O
t O
( O
117 O
) O
= O
7.039 O
; O
P O
< O
0.001 O
# O
Cigarette O
smoking O
days O
/ O
60 O
days O
1.58 O
( O
3.93 O
) O
.34 O
( O
2.67 O
) O
t O
( O
87.28 O
) O
= O
− O
1.979 O
; O
P O
= O
0.051 O
# O
Drinking O
days O
/ O
60 O
days O
12.42 O
( O
16.76 O
) O
7.87 O
( O
14.42 O
) O
t O
( O
119 O
) O
= O
− O
1.603 O
; O
P O
= O
0.112 O
Cannabis O
use O
Duration O
of O
regular O
use O
( O
years O
) O
12.46 O
( O
7.74 O
) O
n O
/ O
a O
n O
/ O
a O
Lifetime O
CUD O
symptom O
count O
2.47 O
( O
2.42 O
) O
n O
/ O
a O
n O
/ O
a O
MJ O
grams O
per O
day O
2.15 O
( O
1.76 O
) O
n O
/ O
a O
n O
/ O
a O
THC O
/ O
creatinine O
ratio O
during O
abstinent O
state O
2.05 O
( O
1.71 O
) O
n O
/ O
a O
n O
/ O
a O
Marijuana O
withdrawal O
checklist O
( O
MWC O
) O
total O
score O
9.6 O
( O
8.96 O
) O
n O
/ O
a O
n O
/ O
a O
Pre‐scan O
marijuana O
craving O
questionnaire O
( O
MCQ O
) O
sum O
237.04 O
( O
154.48 O
) O
n O
/ O
a O
n O
/ O
a O
Post‐scan O
MCQ O
sum O
250.57 O
( O
170.65 O
) O
n O
/ O
a O
n O
/ O
a O
fMRI O
Data O
fMRI O
scan O
acquisition O
The O
users O
were O
scanned O
following O
a O
72 O
‐ O
h O
abstinence O
from O
cannabis O
use O
. O

Although O
there O
is O
no O
reliable O
measure O
of O
acute O
abstinence O
from O
cannabis O
, O
we O
measured O
THC O
metabolites O
as O
ng O
/ O
ml O
( O
over O
creatinine O
) O
( O
via O
GC O
/ O
MS O
) O
from O
the O
participants O
before O
and O
after O
approximately O
72 O
‐ O
h O
period O
to O
detect O
reductions O
in O
THC O
metabolites O
, O
in O
addition O
to O
self‐report O
. O

All O
participants O
were O
asked O
to O
abstain O
from O
alcohol O
for O
24 O
h O
and O
from O
caffeine O
and O
cigarettes O
for O
the O
2 O
‐ O
h O
before O
their O
scheduled O
scan O
. O

Breath O
alcohol O
level O
was O
also O
collected O
to O
confirm O
blood O
alcohol O
content O
of O
0.000 O
at O
the O
beginning O
of O
the O
scan O
. O

Additionally O
, O
all O
participants O
were O
asked O
to O
eat O
a O
meal O
before O
their O
scan O
appointment O
to O
reduce O
confounding O
effects O
of O
hunger O
. O

Scanning O
sessions O
took O
place O
in O
the O
Advanced O
Imaging O
Research O
Center O
( O
AIRC O
) O
on O
the O
main O
University O
of O
Texas O
Southwestern O
Medical O
Center O
( O
UTSW O
) O
campus O
. O

MRI O
images O
were O
collected O
using O
a O
3T O
Philips O
whole O
body O
scanner O
equipped O
with O
Quasar O
gradient O
subsystem O
( O
40 O
mT O
/ O
m O
amplitude O
, O
a O
slew O
rate O
of O
220 O
mT O
/ O
m O
/ O
ms O
) O
. O

Structural B-E
MRI I-E
scans I-E
were O
collected O
with O
a O
MPRAGE O
sequence O
with O
the O
following O
parameters O
: O
TR O
/ O
TE O
/ O
TI O
= O
8.2 O
/ O
3.70 O
/ O
1,100 O
ms O
, O
flip O
angle O
= O
12 O
° O
, O
FOV O
= O
256 O
× O
256 O
mm O
, O
slab O
thickness O
= O
160 O
mm O
( O
along O
left‐right O
direction O
) O
, O
voxel O
size O
= O
1 O
× O
1 O
× O
1 O
mm O
, O
total O
scan O
time O
= O
3 O
min O
57 O
s O
. O
fMRI B-E
scans O
were O
collected O
using O
a O
gradient O
echo O
, O
echo‐planar O
sequence O
with O
the O
intercomissural O
line O
( O
AC‐PC O
) O
as O
a O
reference O
( O
TR O
: O
2.0 O
s O
, O
TE O
: O
29 O
ms O
, O
flip O
angle O
: O
75 O
° O
, O
matrix O
size O
: O
64 O
× O
64 O
, O
39 O
slices O
, O
voxel O
size O
: O
3.44 O
× O
3.44 O
× O
3.5 O
mm3 O
) O
. O
fMRI B-E
cannabis I-E
cue I-E
exposure I-E
task I-E
During I-E
the I-E
fMRI I-E
session I-E
, O
the O
participants O
completed O
a O
cannabis O
cue‐exposure O
task O
modified O
from O
the O
one O
previously O
described O
by O
Filbey O
et O
al O
. O
[ O
2009b O
] O
to O
include O
a O
cue O
for O
a O
natural O
reward O
. O

The O
task O
consisted O
of O
two O
runs O
, O
each O
one O
with O
a O
different O
pseudorandom O
order O
of O
visual O
and O
tactile O
presentations O
of O
: O
( O
i O
) O
a O
single O
cannabis O
cue O
( O
six O
trials O
) O
, O
( O
ii O
) O
a O
single O
natural O
reward O
cue O
( O
six O
trials O
) O
, O
and O
( O
iii O
) O
a O
single O
neutral O
cue O
( O
six O
trials O
) O
. O

Each O
cue O
was O
presented O
for O
twentys O
. O

Following O
the O
cue O
exposure O
period O
, O
we O
measured O
momentary O
subjective O
craving O
by O
asking O
the O
participants O
to O
respond O
to O
: O
“ O
Please O
rate O
your O
urge O
to O
use O
marijuana O
right O
now O
. O
” O

Responses O
were O
measured O
using O
a O
scale O
from O
zero O
( O
no O
urge O
at O
all O
) O
to O
ten O
( O
extremely O
high O
urge O
) O
( O
five O
s O
) O
. O

A O
twenty O
s O
washout O
period O
completed O
each O
trial O
. O

Responses O
were O
recorded O
using O
a O
fiber‐optic O
pad O
. O

The O
participants O
were O
pseudorandomly O
given O
different O
orders O
of O
the O
runs O
( O
e.g O
. O
, O
run O
A O
, O
run O
B O
or O
run O
B O
, O
run O
A O
) O
. O

We O
presented O
task O
stimuli O
to O
the O
participants O
based O
on O
their O
response O
to O
“ O
what O
is O
your O
preferred O
cannabis O
use O
method O
? O
” O

Twenty‐three O
users O
selected O
the O
pipe O
, O
eleven O
selected O
the O
bong O
, O
eleven O
selected O
the O
blunt O
and O
eight O
selected O
the O
joint O
. O

For O
the O
non‐users O
, O
cannabis O
paraphernalia O
were O
matched O
to O
what O
was O
presented O
to O
the O
users O
resulting O
in O
Twenty‐seven O
non‐users O
presented O
with O
the O
pipe O
, O
Twenty‐two O
presented O
with O
the O
bong O
, O
three O
presented O
with O
the O
blunt O
and O
eleven O
presented O
with O
the O
joint O
. O

There O
was O
missing O
information O
on O
five O
of O
the O
participants O
. O

For O
the O
natural O
reward O
cues O
, O
we O
selected O
fruit O
because O
of O
its O
appetitiveness O
and O
because O
it O
exists O
within O
the O
natural O
environment O
and O
would O
have O
inherent O
representations O
in O
the O
human O
brain O
[ O
Filbey O
et O
al O
. O
, O
2012 O
; O
Jiang O
et O
al O
. O
, O
2015 O
] O
. O

Similar O
to O
the O
cannabis O
cues O
, O
we O
presented O
participants O
with O
their O
self‐selected O
fruit O
stimulus O
based O
on O
the O
their O
response O
to O
“ O
what O
is O
your O
preferred O
fruit O
? O
” O

In O
the O
users O
, O
fourteen O
chose O
a O
banana O
, O
twelve O
chose O
an O
apple O
, O
thirteen O
chose O
an O
orange O
, O
and O
thirteen O
chose O
grapes O
. O

In O
the O
non‐users O
, O
sixteen O
selected O
a O
banana O
, O
seventeen O
selected O
an O
apple O
, O
fifteen O
selected O
an O
orange O
, O
and O
twenty O
selected O
grapes O
. O

Lastly O
, O
similar O
to O
the O
original O
task O
, O
a O
pencil O
was O
used O
as O
a O
neutral O
cue O
for O
all O
of O
the O
participants O
. O

Stimulus O
presentations O
were O
delivered O
using O
E‐Prime O
( O
Psychology O
Software O
Tools O
) O
. O

The O
timing O
of O
the O
stimulus O
presentation O
was O
synchronized O
with O
trigger O
pulses O
from O
the O
magnet O
to O
ensure O
precise O
temporal O
integration O
of O
stimulus O
presentation O
and O
fMRI O
data O
acquisition O
. O
fMRI O
Data O
Analysis O
Pre‐processing O
The O
functional O
imaging O
time O
series O
was O
pre‐processed O
using O
SPM8 O
( O
Wellcome O
Department O
of O
Imaging O
Neuroscience O
, O
London O
, O
UK O
) O
. O

Before O
starting O
analyses O
, O
the O
first O
seven O
volumes O
of O
each O
EPI O
run O
were O
discarded O
to O
allow O
the O
MR O
signal O
to O
reach O
steady O
state O
. O

Pre‐processing O
of O
these O
volumes O
started O
with O
motion O
correction O
using O
SPM's O
realignment O
module O
[ O
Friston O
et O
al O
. O
, O
1995 O
] O
. O

This O
was O
followed O
by O
slice O
timing O
correction O
, O
which O
corrected O
for O
temporal O
differences O
in O
acquisition O
time O
of O
the O
BOLD O
signal O
across O
slices O
within O
each O
volume O
. O

The O
resultant O
time O
series O
was O
then O
smoothed O
using O
a O
6 O
mm O
full O
width O
half O
maximum O
( O
FWHM O
) O
Gaussian O
kernel O
. O

First‐level O
analyses O
Preprocessed O
time O
series O
for O
each O
participant O
were O
analyzed O
using O
multiple O
linear O
regression O
as O
implemented O
in O
FILM O
( O
FMRIB's O
Improved O
Linear O
Model O
) O
, O
a O
component O
of O
FSL O
. O

Regressors O
for O
the O
linear O
model O
were O
generated O
using O
FEAT O
by O
convolving O
the O
cue O
states O
( O
Cue O
Present O
, O
Craving O
Rating O
, O
Cue O
Washout O
) O
of O
each O
cue O
type O
( O
cannabis O
cues O
, O
neutral O
object O
cues O
and O
fruit O
cues O
) O
with O
a O
double O
gamma O
hemodynamic O
response O
function O
. O

Parameter O
estimates O
for O
the O
regressors O
were O
used O
to O
generate O
z‐maps O
based O
on O
three O
contrasts O
of O
interest O
: O
Cue O
ON O
cannabis O
versus O
Cue O
ON O
neutral O
object O
; O
Cue O
ON O
cannabis O
versus O
Cue O
ON O
fruit O
; O
and O
Cue O
ON O
fruit O
versus O
Cue O
ON O
neutral O
object O
. O

Group O
level O
analyses O
Participant O
contrast O
maps O
were O
registered O
to O
their O
own O
MRI B-E
T1 I-E
weighted I-E
MPRAGE O
structural O
images O
, O
and O
then O
co‐registered O
to O
the O
MNI O
152 O
template O
space O
using O
FLIRT O
( O
FMRIB's O
Linear O
Image O
Registration O
Tool O
) O
. O

Group O
analysis O
of O
contrasts O
was O
performed O
in O
FEAT O
using O
FLAME O
( O
FMRIB's O
Local O
Analysis O
of O
Mixed O
Effects O
) O
to O
estimate O
a O
mixed O
effects O
model O
of O
task‐related O
activation O
differences O
for O
each O
of O
the O
three O
contrasts O
of O
interest O
( O
as O
a O
Gaussianized O
t O
/ O
F O
statistic O
) O
. O

Groups O
were O
defined O
by O
cannabis O
usage O
status O
( O
user O
/ O
non‐user O
) O
. O

Contrast O
maps O
were O
generated O
for O
each O
usage O
status O
. O

Resulting O
maps O
were O
height‐thresholded O
at O
a O
Z‐value O
of O
2.3 O
. O

We O
used O
FEAT's O
cluster‐thresholding O
method O
, O
which O
estimated O
activated O
clusters O
’ O
significance O
level O
( O
from O
Gaussian O
random O
field O
theory O
) O
compared O
with O
the O
cluster O
probability O
threshold O
[ O
Worsley O
et O
al O
. O
, O
1996 O
] O
) O
of O
P O
≤ O
0.05 O
. O

Because O
a O
height‐threshold O
of O
z O
= O
2.3 O
may O
result O
in O
large O
clusters O
despite O
adequately O
controlling O
for O
false‐positives O
, O
we O
also O
used O
a O
cluster O
defining O
voxel O
threshold O
of O
P O
≤ O
0.001 O
per O
recommendations O
by O
Woo O
et O
al O
. O
[ O
2014 O
] O
for O
the O
enhancement O
of O
anatomical O
specificity O
. O

In O
addition O
to O
simple O
group O
level O
maps O
, O
within O
the O
cannabis O
users O
, O
group O
level O
contrasts O
were O
generated O
for O
several O
variables O
of O
interest O
. O

To O
determine O
the O
relationship O
between O
the O
neural O
response O
in O
brain O
areas O
and O
subjective O
craving O
, O
group O
maps O
were O
regressed O
separately O
against O
total O
MCQ O
scores O
( O
baseline O
craving O
) O
and O
in‐scanner O
cannabis O
craving O
ratings O
. O

To O
determine O
if O
the O
neural O
response O
in O
brain O
areas O
are O
modulated O
by O
cannabis O
use O
behavior O
, O
group O
maps O
were O
regressed O
separately O
against O
reported O
grams O
of O
cannabis O
use O
per O
day O
and O
THC O
/ O
creatinine O
levels O
from O
the O
abstinent O
state O
. O

To O
determine O
the O
clinical O
relevance O
of O
the O
neural O
response O
to O
cannabis O
cues O
, O
group O
maps O
were O
regressed O
separately O
against O
MWC O
scores O
and O
MPS O
scores O
. O

We O
expected O
positive O
associations O
between O
neural O
response O
to O
cues O
and O
subjective O
craving O
, O
cannabis O
use O
behavior O
and O
clinical O
symptoms O
of O
CUD O
. O

A O
Robust O
Sparse-Modeling O
Framework O
for O
Estimating O
Schizophrenia B-E
Biomarkers O
from O
fMRI B-E
Background O
Our O
goal O
is O
to O
identify O
the O
brain O
regions O
most O
relevant O
to O
mental O
illness O
using O
neuroimaging O
. O

State O
of O
the O
art O
machine O
learning O
methods O
commonly O
suffer O
from O
repeatability O
difficulties O
in O
this O
application O
, O
particularly O
when O
using O
large O
and O
heterogeneous O
populations O
for O
samples O
. O

New O
Method O
We O
revisit O
both O
dimensionality O
reduction O
and O
sparse O
modeling O
, O
and O
recast O
them O
in O
a O
common O
optimization-based O
framework O
. O

This O
allows O
us O
to O
combine O
the O
benefits O
of O
both O
types O
of O
methods O
in O
an O
approach O
which O
we O
call O
unambiguous O
components O
. O

We O
use O
this O
to O
estimate O
the O
image O
component O
with O
a O
constrained O
variability O
, O
which O
is O
best O
correlated O
with O
the O
unknown O
disease O
mechanism O
. O

Results O
We O
apply O
the O
method O
to O
the O
estimation O
of O
neuroimaging O
biomarkers O
for O
schizophrenia B-E
, O
using O
task B-E
fMRI I-E
data O
from O
a O
large O
multi-site O
study O
. O

The O
proposed O
approach O
yields O
an O
improvement O
in O
both O
robustness O
of O
the O
estimate O
and O
classification O
accuracy O
. O

Comparison O
with O
Existing O
Methods O
We O
find O
that O
unambiguous O
components O
incorporate O
roughly O
two O
thirds O
of O
the O
same O
brain O
regions O
as O
sparsity-based O
methods O
LASSO O
and O
elastic O
net O
, O
while O
roughly O
one O
third O
of O
the O
selected O
regions O
differ O
. O

Further O
, O
unambiguous O
components O
achieve O
superior O
classification O
accuracy O
in O
differentiating O
cases O
from O
controls O
. O

Conclusions O
Unambiguous O
components O
provide O
a O
robust O
way O
to O
estimate O
important O
regions O
of O
imaging O
data O
. O
1 O
. O

Materials B-E
and I-E
Methods I-E
We O
will O
consider O
the O
linear O
model O
Ax O
= O
b O
+ O
n O
where O
A O
is O
a O
m O
× O
n O
data O
matrix O
with O
n O
> O
m O
, O
containing O
samples O
as O
rows O
, O
and O
variables O
as O
columns O
; O
b O
is O
the O
phenotype O
encoded O
into O
a O
vector O
of O
labels O
such O
as O
case O
or O
control O
; O
the O
solution O
x O
is O
the O
unknown O
model O
parameters O
that O
relate O
A O
to O
b O
; O
and O
n O
is O
a O
noise O
vector O
about O
which O
we O
have O
only O
statistical O
information O
. O

We O
will O
also O
assume O
the O
means O
have O
been O
removed O
from O
b O
and O
the O
columns O
of O
A O
to O
simplify O
the O
presentation O
. O

The O
rows O
of O
A O
are O
provided O
by O
the O
contrast O
images O
from O
individual O
study O
subjects O
, O
so O
a O
predictor O
x O
selects O
a O
weighted O
combination O
of O
voxels O
( O
i.e O
. O
, O
columns O
of O
A O
) O
which O
relates O
the O
imagery O
to O
the O
case-control O
status O
. O

By O
examining O
the O
weightings O
in O
this O
combination O
we O
hope O
to O
learn O
more O
about O
the O
spatial O
distribution O
of O
causes O
or O
effects O
of O
the O
disease O
, O
which O
we O
will O
term O
the O
“ O
mechanism O
” O
in O
this O
paper O
. O

The O
model O
is O
depicted O
in O
Fig O
. O
1 O
( O
a O
) O
, O
where O
we O
depict O
the O
true O
solution O
x O
as O
the O
mechanism O
whereby O
brain O
activity O
relates O
to O
the O
measured O
phenotypes O
. O

Of O
course O
there O
are O
far O
more O
unknown O
variables O
than O
samples O
, O
hence O
our O
linear O
system O
is O
underdetermined O
and O
there O
will O
be O
many O
possible O
x O
which O
solve O
the O
system O
. O

One O
way O
to O
address O
this O
problem O
is O
to O
impose O
prior O
knowledge O
about O
the O
biological O
mechanism O
, O
such O
as O
a O
preference O
for O
sparser O
x O
, O
and O
select O
the O
solution O
which O
best O
fulfills O
this O
preference O
. O

We O
will O
review O
this O
approach O
in O
a O
later O
section O
. O

Another O
approach O
is O
to O
restrict O
our O
analysis O
to O
components O
of O
the O
solution O
which O
may O
be O
more O
easily O
estimated O
, O
such O
as O
via O
dimensionality O
reduction O
; O
an O
intuitive O
example O
of O
this O
approach O
is O
to O
group O
voxels O
into O
low-resolution O
regions O
. O

These O
alternatives O
are O
depicted O
in O
Fig O
. O
1 O
( O
b O
) O
, O
as O
extremes O
on O
a O
continuum O
of O
possible O
methods O
, O
where O
the O
goal O
of O
this O
paper O
is O
to O
find O
intermediate O
information O
which O
utilizes O
the O
benefits O
of O
both O
extremes O
. O
2.1 O
. O

Dimensionality O
Reduction O
To O
see O
how O
dimensionality O
reduction O
can O
apply O
to O
the O
estimation O
of O
mechanism O
, O
consider O
the O
Singular O
Value O
Decomposition O
( O
SVD O
) O
of O
A O
= O
USVT O
, O
where O
S O
is O
a O
diagonal O
matrix O
of O
singular O
values O
σi O
, O
and O
U O
and O
V O
contain O
the O
left O
and O
right O
singular O
vectors O
ui O
and O
vi O
. O

In O
Principal O
Components O
Analysis O
( O
PCA O
) O
the O
focus O
is O
on O
this O
expansion O
itself O
, O
however O
our O
focus O
here O
is O
on O
the O
mechanism O
which O
we O
model O
by O
x O
. O

If O
we O
plug O
USVT O
into O
Ax O
= O
b O
and O
apply O
the O
transformation O
UT O
to O
both O
sides O
, O
we O
get O
a O
diagonalized O
system O
with O
decoupled O
equations O
of O
the O
form O
. O

This O
equation O
tell O
us O
that O
, O
while O
we O
can't O
calculate O
the O
true O
x O
in O
the O
underdetermined O
case O
, O
we O
can O
calculate O
components O
of O
x O
corresponding O
to O
nonzero O
singular O
values O
. O

One O
way O
to O
view O
this O
property O
is O
by O
considering O
that O
these O
components O
are O
constant O
for O
all O
possible O
x O
given O
our O
linear O
system O
. O

In O
other O
words O
, O
calculates O
the O
same O
value O
for O
any O
solution O
in O
the O
set O
{ O
x O
| O
Ax O
= O
b O
} O
. O

In O
terms O
of O
our O
application O
, O
this O
means O
while O
we O
can't O
identify O
the O
true O
mechanism O
x O
, O
we O
can O
extract O
reliable O
components O
of O
it O
. O

For O
example O
, O
we O
might O
be O
able O
to O
coarsely O
identify O
large O
regions O
containing O
important O
activity O
, O
without O
being O
able O
to O
pinpoint O
particular O
voxels O
within O
those O
regions O
. O

Of O
course O
the O
SVD O
selects O
vectors O
based O
on O
orthogonal O
directions O
of O
ranked O
data O
variation O
, O
which O
may O
not O
be O
best O
suited O
to O
provide O
information O
about O
the O
disease O
mechanism O
. O

We O
will O
address O
this O
later O
by O
optimizing O
the O
choice O
of O
component O
, O
but O
first O
we O
will O
formally O
consider O
this O
property O
of O
constant O
components O
so O
that O
we O
may O
extend O
it O
later O
to O
incorporate O
prior O
knowledge O
. O
2.2 O
. O

Unambiguous O
Components O
without O
Prior O
Knowledge O
In O
this O
section O
we O
will O
introduce O
the O
idea O
of O
unambiguous O
components O
in O
the O
noise-free O
case O
without O
prior O
knowledge O
. O

The O
concept O
is O
demonstrated O
geometrically O
in O
Fig O
. O
2 O
( O
a O
) O
, O
where O
the O
useful O
information O
in O
A O
forms O
the O
matrix O
rowspace O
; O
this O
contains O
the O
dimensions O
over O
which O
we O
have O
a O
diversity O
of O
data O
which O
we O
can O
compare O
to O
the O
phenotype O
b O
. O

Dimensions O
perpendicular O
to O
the O
rowspace O
form O
the O
nullspace O
, O
directions O
over O
which O
our O
data O
does O
not O
vary O
. O

For O
example O
if O
our O
dataset O
was O
composed O
of O
subjects O
with O
the O
same O
age O
, O
then O
we O
cannot O
perform O
a O
regression O
to O
see O
how O
disease O
risk O
relates O
to O
age O
. O

In O
terms O
of O
components O
of O
the O
data O
, O
if O
c O
is O
a O
loading O
vector O
and O
ai O
is O
a O
sample O
( O
row O
of O
A O
) O
, O
then O
cTai O
is O
potentially O
useful O
information O
when O
c O
is O
in O
the O
rowspace O
, O
and O
useless O
information O
( O
in O
fact O
always O
zero O
) O
when O
c O
is O
in O
the O
nullspace O
. O

An O
equivalent O
perspective O
, O
depicted O
in O
Fig O
. O
2 O
( O
b O
) O
, O
is O
the O
geometry O
of O
the O
solution O
set O
to O
the O
regression O
model O
. O

This O
is O
the O
affine O
set O
SEC O
, O
composed O
of O
an O
offset O
( O
the O
least-length O
solution O
x0 O
) O
plus O
a O
vector O
from O
the O
nullspace O
. O

The O
subscript O
“ O
EC O
” O
refers O
to O
x O
being O
only O
equality-constrained O
( O
i.e O
. O
, O
we O
have O
imposed O
no O
prior O
knowledge O
yet O
) O
. O

The O
rowspace O
vectors O
yield O
estimable O
components O
of O
x O
given O
the O
data O
, O
while O
nullspace O
vectors O
give O
the O
dimensions O
of O
ambiguity O
we O
have O
about O
x O
. O

We O
will O
formulate O
this O
relationship O
rigorously O
next O
. O

Recall O
that O
the O
rowspace O
of O
A O
is O
defined O
as O
the O
set O
of O
all O
possible O
linear O
combinations O
of O
rows O
, O
i.e O
. O
, O
. O

We O
can O
equivalently O
view O
this O
as O
a O
set O
whose O
members O
take O
on O
a O
constant O
value O
over O
SEC O
. O

In O
other O
words O
, O
they O
form O
the O
set O
of O
unambiguous O
components O
for O
SEC O
. O

We O
state O
this O
simple O
but O
important O
fact O
in O
Theorem O
1 O
. O

Theorem O
1 O
. O
cTx O
= O
μ O
for O
all O
x O
∈ O
SEC O
, O
where O
μ O
is O
a O
constant O
. O

The O
following O
two O
statements O
are O
equivalent O
: O
Proof O
It O
is O
straightforward O
to O
note O
that O
, O
as O
ATy O
= O
c O
, O
we O
have O
cTx O
= O
yTAx O
= O
yTb O
≡ O
μ O
. O

However O
it O
will O
be O
useful O
to O
our O
subsequent O
extension O
to O
note O
the O
fact O
that O
the O
rows-pace O
is O
the O
orthogonal O
complement O
to O
the O
nullspace O
, O
and O
can O
be O
also O
written O
as O
. O

Equivalently O
, O
any O
vector O
z O
in O
the O
nullspace O
may O
be O
described O
as O
a O
difference O
between O
solutions O
, O
i.e O
. O
, O
z O
= O
x1 O
– O
x2 O
, O
where O
x1 O
, O
x2 O
∈ O
SEC O
. O

Therefore O
the O
rowspace O
may O
also O
be O
written O
as O
, O
which O
explicitly O
states O
the O
equivalence O
in O
Theorem O
1 O
. O

The O
principal O
components O
of O
A O
corresponding O
to O
the O
r O
nonzero O
singular O
values O
must O
be O
in O
the O
rowspace O
. O

Again O
, O
given O
a O
singular-value O
decomposition O
A O
= O
USVT O
, O
we O
have O
VSUTy O
= O
c O
for O
, O
and O
hence O
, O
where O
the O
ui O
for O
i O
∈ O
{ O
1 O
, O
. O
. O
. O
, O
r O
} O
form O
a O
basis O
for O
the O
rowspace O
. O

So O
principal O
components O
are O
unambiguous O
components O
. O

Later O
we O
will O
also O
consider O
how O
to O
optimize O
the O
choice O
of O
component O
such O
that O
it O
also O
computes O
a O
score O
which O
is O
maximally O
useful O
for O
an O
application O
( O
such O
as O
to O
identify O
important O
image O
regions O
for O
classification O
of O
disease O
) O
. O

But O
first O
we O
will O
extend O
the O
concept O
of O
unambiguous O
components O
to O
incorporate O
prior O
knowledge O
. O

Our O
focus O
on O
components O
of O
the O
mechanism O
x O
rather O
than O
of O
the O
data O
ai O
allows O
us O
to O
incorporate O
prior O
knowledge O
which O
applies O
to O
x O
into O
the O
method O
, O
such O
as O
the O
presumption O
of O
a O
sparse O
biological O
mechanism O
. O

In O
effect O
, O
we O
will O
utilize O
prior O
knowledge O
to O
further O
restrict O
the O
variation O
in O
x O
and O
potentially O
increase O
the O
estimable O
components O
of O
x O
. O
2.3 O
. O

LASSO O
and O
Elastic O
Net O
In O
this O
section O
we O
will O
review O
closely-related O
estimation O
methods O
which O
utilize O
prior O
knowledge O
, O
to O
provide O
an O
intuitive O
basis O
for O
our O
mathematical O
formulation O
. O

The O
Maximum O
A O
Posteriori O
( O
MAP O
) O
estimate O
xMAP O
is O
the O
solution O
which O
maximizes O
the O
posterior O
probability O
P O
( O
x O
| O
b O
) O
over O
x O
. O

Using O
Bayes O
’ O
theorem O
, O
we O
can O
form O
the O
equivalent O
problem O
, O
arg O
maxx O
P O
( O
b O
| O
x O
) O
P O
( O
x O
) O
, O
which O
utilizes O
the O
likelihood O
P O
( O
b O
| O
x O
) O
( O
essentially O
the O
distribution O
for O
n O
) O
, O
and O
the O
prior O
probability O
distribution O
P O
( O
x O
) O
. O

It O
is O
the O
form O
of O
this O
prior O
distribution O
which O
we O
refer O
to O
as O
the O
prior O
knowledge O
. O

A O
common O
approach O
is O
to O
take O
the O
log O
of O
this O
objective O
to O
get O
a O
penalized O
regression O
problem O
. O

With O
a O
Gaussian O
distribution O
for O
n O
and O
a O
Laplace O
distribution O
for O
x O
, O
taking O
the O
log O
yields O
the O
most O
well-known O
version O
of O
LASSO O
, O
. O

LASSO O
was O
originally O
proposed O
in O
the O
form O
, O
subject O
to O
, O
with O
the O
other O
version O
sometimes O
described O
as O
the O
Lagrangian O
form O
. O

It O
can O
be O
shown O
that O
for O
any O
λ O
, O
a O
α1 O
exists O
such O
that O
these O
optimization O
problems O
have O
the O
same O
minimizer O
, O
x1 O
. O

We O
can O
similarly O
form O
the O
feasibility O
problem O
( O
an O
optimization O
problem O
which O
stops O
when O
any O
feasible O
point O
is O
found O
, O
hence O
we O
simply O
use O
a O
zero O
for O
the O
objective O
as O
it O
is O
irrelevant O
) O
, O
In O
this O
paper O
we O
will O
focus O
on O
sets O
of O
the O
general O
form O
of O
this O
feasible O
set O
we O
will O
denote O
as O
SDR O
. O

In O
terms O
of O
the O
statistical O
distributions O
, O
the O
constraints O
on O
the O
norms O
amount O
to O
constraints O
on O
the O
probabilities O
, O
as O
in O
The O
subscript O
DR O
refers O
to O
the O
combination O
of O
denoising O
and O
regularization O
constraints O
. O

It O
can O
also O
be O
shown O
that O
x1 O
which O
solves O
the O
previous O
versions O
, O
will O
provide O
a O
member O
of O
this O
set O
. O

Therefore O
, O
we O
may O
write O
the O
LASSO O
problem O
as O
The O
elastic O
net O
can O
be O
viewed O
as O
a O
variation O
on O
LASSO O
, O
where O
( O
under O
the O
Bayesian O
framework O
) O
the O
Laplace O
prior O
distribution O
for O
the O
prior O
is O
replaced O
by O
a O
product O
of O
Laplace O
and O
Gaussian O
distributions O
. O

Taking O
the O
log O
of O
the O
posterior O
distribution O
leads O
to O
the O
well-known O
problem O
. O

As O
with O
LASSO O
, O
we O
may O
achieve O
the O
same O
solution O
using O
different O
optimization O
problems O
. O

We O
wish O
to O
use O
the O
same O
constraints O
as O
earlier O
, O
so O
we O
form O
the O
related O
problem O
, O
Recall O
that O
LASSO O
seeks O
any O
single O
solution O
within O
SDR O
. O

In O
that O
case O
, O
α1 O
and O
α2 O
are O
chosen O
as O
small O
as O
possible O
so O
the O
set O
is O
( O
hopefully O
) O
a O
singleton O
. O

Elastic O
net O
, O
on O
the O
other O
hand O
, O
seeks O
the O
least O
length O
solution O
in O
SDR O
, O
where O
we O
may O
choose O
α1 O
and O
α2 O
more O
loosely O
, O
to O
trade-off O
desirable O
properties O
of O
this O
solution O
. O

These O
are O
depicted O
in O
Fig O
. O
2 O
( O
d O
) O
, O
where O
the O
LASSO O
solution O
, O
x1 O
is O
formed O
by O
tightening O
the O
bounds O
on O
the O
two O
sets O
( O
one O
representing O
the O
prior O
and O
one O
representing O
the O
noise O
) O
to O
minimal O
intersection O
. O

The O
elastic O
net O
solution O
, O
by O
contrast O
, O
relaxes O
the O
constraints O
on O
the O
two O
sets O
forming O
the O
larger O
set O
SDR O
, O
and O
selection O
of O
the O
least O
length O
solution O
in O
this O
intersection O
. O

Next O
we O
will O
extend O
the O
unambiguous O
component O
idea O
to O
utilize O
SDR O
, O
thereby O
incorporating O
prior O
knowledge O
into O
the O
framework O
. O

Finally O
, O
note O
that O
the O
norms O
∥ O
· O
∥ O
1 O
and O
∥ O
· O
∥ O
2 O
may O
be O
replaced O
with O
other O
choices O
of O
norms O
representing O
other O
forms O
of O
prior O
knowledge O
, O
such O
as O
the O
ℓ O
∞ O
- O
norm O
, O
which O
imposes O
hard O
limits O
on O
the O
unknowns O
or O
the O
error O
, O
and O
which O
might O
result O
from O
box O
constraints O
or O
a O
minimax O
regression O
. O

